Evidence map›Paper›PMID 34741666›Full record

ArticleInternational journal of legal medicine2022

Development and validation of a novel 133-plex forensic STR panel (52 STRs and 81 Y-STRs) using single-end 400 bp massive parallel sequencing.

Haoliang Fan, Lingxiang Wang, Changhui Liu, Xiaoyu Lu, Xuding Xu, Kai Ru, Pingming Qiu, Chao Liu, Shao-Qing Wen

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of legal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haoliang Fan *Institute of Archaeological Science, Fudan University, Shanghai, 200433, China.ORCID http://orcid.org/0000-0002-3214-0177
Lingxiang Wang *Institute of Archaeological Science, Fudan University, Shanghai, 200433, China.
Changhui Liu *School of Forensic Medicine, Southern Medical University, Guangzhou, 510515, China.
Xiaoyu LuInstitute of Archaeological Science, Fudan University, Shanghai, 200433, China.ORCID http://orcid.org/0000-0003-3701-5217
Xuding XuInstitute of Archaeological Science, Fudan University, Shanghai, 200433, China.
Kai RuInstitute of Archaeological Science, Fudan University, Shanghai, 200433, China.
Pingming QiuSchool of Forensic Medicine, Southern Medical University, Guangzhou, 510515, China.ORCID http://orcid.org/0000-0002-5579-1124
Chao LiuSchool of Forensic Medicine, Southern Medical University, Guangzhou, 510515, China. liuchaogzf@163.com.ORCID http://orcid.org/0000-0001-5633-3929
Shao-Qing WenInstitute of Archaeological Science, Fudan University, Shanghai, 200433, China. wenshaoqing@fudan.edu.cn.ORCID http://orcid.org/0000-0003-1223-4720

Funding

National Natural Science Foundation of China 32070576National Undergraduate Innovation and Entrepreneurship Training Program 201911810008National Undergraduate Innovation and Entrepreneurship Training Program 201911810023Program of Hainan Association for Science and Technology Plans to Youth R&D Innovation QCXM201705Science and Technology Program of Guangzhou, China 2019030016
6 · The paper itself

Abstract

Short tandem repeats (STRs) are the preferred genetic markers in forensic DNA analysis, routinely measured by capillary electrophoresis (CE) method based on the fragment length features. While, the massive parallel sequencing (MPS) technology could simultaneously target a large number of intriguing forensic STRs, bypassing the intrinsic limitations of amplicon size separation and accessible fluorophores in CE, which is efficient and promising for enabling the identification of forensic biological evidence. Here, we developed a novel MPS-based Forensic Analysis System Multiplecues SetB Kit of 133-plex forensic STR markers (52 STRs and 81 Y-STRs) and one Y-InDel (M175) based on multiplex PCR and single-end 400 bp sequencing strategy. This panel was subjected to developmental validation studies according to the SWGDAM Validation Guidelines. Approximately 2185 MPS-based reactions using 6 human DNA standards and 8 male donors were conducted for substrate studies (filter paper, gauze, cotton swab, four different types of FTA cards, peripheral venous blood, saliva, and exfoliated cells), sensitivity studies (from 2 ng down to 0.0625 ng), mixture studies (two-person DNA mixtures), PCR inhibitor studies (seven commonly encountered PCR inhibitors), species specificity studies (11 non-human species), and repeatability studies. Results of concordance studies (413 Han males and 6 human DNA standards) generated by STRait Razor and in-house Python scripts indicated 99.98% concordance rate in STR calling relative to CE for STRs between 41,900 genotypes at 100 STR markers. Moreover, the limitations of present studies, the nomenclature rules and forensic MPS applications were also described. In conclusion, the validation studies based on ~ 2200 MPS-based and ~ 2500 CE-based DNA profiles demonstrated that the novel MPS-based panel meets forensic DNA quality assurance guidelines with robust, reliable, and reproducible performance on samples of various quantities and qualities, and the STR nomenclature rules should be further regulated to integrate the inconformity between MPS-based and CE-based methods.

Indexed as

High-Throughput Nucleotide SequencingMicrosatellite RepeatsDNA FingerprintingForensic GeneticsHumansMaleMultiplex Polymerase Chain ReactionSequence Analysis, DNASpecies SpecificityForensic geneticsMassive parallel sequencingMultiplex PCRNext-generation sequencingSingle-end 400 bpSTRValidation studyY-STR

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.